Cargando…

Optimization of prostate cancer cell detection using multiplex tyramide signal amplification

Approximately 29 000 men die of prostate cancer (PCa) each year in the United States, and 90% to 100% of them are due to incurable bone metastasis. It is difficult to determine (1) when PCa disseminates in the natural history of the disease; (2) where cancer cell disseminates before becoming overt m...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Sounak, Axelrod, Haley D., Valkenburg, Kenneth C., Amend, Sarah, Pienta, Kenneth J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519224/
https://www.ncbi.nlm.nih.gov/pubmed/30390333
http://dx.doi.org/10.1002/jcb.28016
_version_ 1783418602127360000
author Roy, Sounak
Axelrod, Haley D.
Valkenburg, Kenneth C.
Amend, Sarah
Pienta, Kenneth J.
author_facet Roy, Sounak
Axelrod, Haley D.
Valkenburg, Kenneth C.
Amend, Sarah
Pienta, Kenneth J.
author_sort Roy, Sounak
collection PubMed
description Approximately 29 000 men die of prostate cancer (PCa) each year in the United States, and 90% to 100% of them are due to incurable bone metastasis. It is difficult to determine (1) when PCa disseminates in the natural history of the disease; (2) where cancer cell disseminates before becoming overt metastatic lesions; and (3) which tumors are aggressive and which are indolent. Tumor tissue and liquid (blood and bone marrow) biopsies provide important information to answer these questions, but significant limitations exist for immunostaining strategies that assess protein expression in these tissues. Classic immunohistochemistry (IHC) assays can typically assess expression of one or two proteins per tissue section. We have developed a novel immunofluorescence staining protocol to detect a panel of seven proteins on PCa tissue from primary tumor biopsies and metastatic lesion autopsy tissue, as well as cancer cells from liquid biopsies. We used a tyramide‐based system to amplify the true signal and optimized the protocol to reduce background signal, thereby boosting the signal‐to‐noise ratio. Any protein‐specific antibody in this protocol can be exchanged for a different validated antibody. This protocol therefore, represents a highly informative and flexible assay that can be used to provide important information about cancer tissue for the purpose of improving detection, diagnosis, and treatment.
format Online
Article
Text
id pubmed-6519224
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-65192242019-05-21 Optimization of prostate cancer cell detection using multiplex tyramide signal amplification Roy, Sounak Axelrod, Haley D. Valkenburg, Kenneth C. Amend, Sarah Pienta, Kenneth J. J Cell Biochem Benchmarks Approximately 29 000 men die of prostate cancer (PCa) each year in the United States, and 90% to 100% of them are due to incurable bone metastasis. It is difficult to determine (1) when PCa disseminates in the natural history of the disease; (2) where cancer cell disseminates before becoming overt metastatic lesions; and (3) which tumors are aggressive and which are indolent. Tumor tissue and liquid (blood and bone marrow) biopsies provide important information to answer these questions, but significant limitations exist for immunostaining strategies that assess protein expression in these tissues. Classic immunohistochemistry (IHC) assays can typically assess expression of one or two proteins per tissue section. We have developed a novel immunofluorescence staining protocol to detect a panel of seven proteins on PCa tissue from primary tumor biopsies and metastatic lesion autopsy tissue, as well as cancer cells from liquid biopsies. We used a tyramide‐based system to amplify the true signal and optimized the protocol to reduce background signal, thereby boosting the signal‐to‐noise ratio. Any protein‐specific antibody in this protocol can be exchanged for a different validated antibody. This protocol therefore, represents a highly informative and flexible assay that can be used to provide important information about cancer tissue for the purpose of improving detection, diagnosis, and treatment. John Wiley and Sons Inc. 2018-11-02 2019-04 /pmc/articles/PMC6519224/ /pubmed/30390333 http://dx.doi.org/10.1002/jcb.28016 Text en © 2018 The Authors. Journal of Cellular Biochemistry Published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Benchmarks
Roy, Sounak
Axelrod, Haley D.
Valkenburg, Kenneth C.
Amend, Sarah
Pienta, Kenneth J.
Optimization of prostate cancer cell detection using multiplex tyramide signal amplification
title Optimization of prostate cancer cell detection using multiplex tyramide signal amplification
title_full Optimization of prostate cancer cell detection using multiplex tyramide signal amplification
title_fullStr Optimization of prostate cancer cell detection using multiplex tyramide signal amplification
title_full_unstemmed Optimization of prostate cancer cell detection using multiplex tyramide signal amplification
title_short Optimization of prostate cancer cell detection using multiplex tyramide signal amplification
title_sort optimization of prostate cancer cell detection using multiplex tyramide signal amplification
topic Benchmarks
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6519224/
https://www.ncbi.nlm.nih.gov/pubmed/30390333
http://dx.doi.org/10.1002/jcb.28016
work_keys_str_mv AT roysounak optimizationofprostatecancercelldetectionusingmultiplextyramidesignalamplification
AT axelrodhaleyd optimizationofprostatecancercelldetectionusingmultiplextyramidesignalamplification
AT valkenburgkennethc optimizationofprostatecancercelldetectionusingmultiplextyramidesignalamplification
AT amendsarah optimizationofprostatecancercelldetectionusingmultiplextyramidesignalamplification
AT pientakennethj optimizationofprostatecancercelldetectionusingmultiplextyramidesignalamplification